{"id":"F2022L00861","name":"Customs By-law No. 2200084","slug":"customs-by-law-no-2200084","collection":"legislative_instrument","jurisdiction":"commonwealth","status":"in_force","isInForce":true,"actNumber":null,"makingDate":null,"administeringDepartment":null,"currentVersion":{"id":102499,"registerId":"commonwealth-F2022L00861-current","compilationNumber":null,"startDate":"2026-04-03","status":"InForce","reasons":null,"registeredAt":null},"sections":[{"sectionNumber":"1","sectionType":"section","heading":"Customs By-law No. 2200084","content":"CUSTOMS ACT 1901\n\nCUSTOMS TARIFF ACT 1995\n\nSCHEDULE 4\n\nBY-LAW No. 2200084\n\nI, Franco Alvarez, delegate of the Comptroller‑General of Customs, under section 271 of the Customs Act 1901, make the by-law set out in the Schedule to this instrument.\n\nThis by-law commences on 1 July 2022.\n\nDated this 28th day of June 2022.\n\n\\[signed\\]\n\nFranco Alvarez\n\nDelegate of the\n\nComptroller-General of Customs\n\nSCHEDULE\n\nItem 57\n\nSchedule 4\n\n1. This by-law may be cited as Customs By-law No. 2200084.\n\n2. For the purposes of item 57 of Schedule 4 to the Customs Tariff Act 1995 (the Customs Tariff), goods of the following kind are prescribed:\n\n(a) the goods are primary receptacles to be used for containing medicaments, vaccines or other goods (the contained goods);\n\n(b) the contained goods, if imported, would be classified under Chapter 30 of Schedule 3 to the Customs Tariff; and\n\n(c) the contained goods are to be used in the treatment, prevention, or to limit the severity of the disease known as COVID‑19.\n\n3. For the purposes of paragraph 2, a primary receptacle means a complete container, whether assembled or not, that directly holds, or would hold, the contained goods. However, a primary receptacle does not include an ingestible capsule for enclosing medicaments.\n\n4. In this by-law, the Customs Tariff Act 1995 means the Customs Tariff Act 1995, as amended or proposed to be altered.","sortOrder":0}],"analysis":{"kimi_summary":{"content_quality":"ok","complexity_score":2,"scope_assessment":{"changed":false,"description":"This by-law maintains its original narrow scope. It was clearly designed from inception to provide temporary tariff relief for COVID-19 related medical packaging, and it does exactly that without expanding into broader pharmaceutical packaging or other disease areas."},"complexity_factors":["Very short instrument (4 operative provisions plus preamble)","Only 1 defined term ('primary receptacle') with a simple exclusion","Single cross-reference to Customs Tariff Act 1995 and Chapter 30 of Schedule 3","No nested conditions or exceptions beyond the simple capsule exclusion","Straightforward purpose-based test (COVID-19 use) with clear classification requirement"],"plain_english_summary":"This by-law grants reduced or zero import duties for certain containers (primary receptacles) specifically designed to hold COVID-19 vaccines, medicaments, and related medical goods. It affects importers and pharmaceutical firms bringing in vials, bottles, syringes, and similar packaging, but excludes ingestible capsules and does not cover the medicines themselves. The relief lowered costs for essential packaging during the pandemic, helping maintain supply of vaccine and treatment materials."},"flash_summary":{"complexity_score":3,"scope_assessment":{"changed":false,"description":"The by-law does not broaden the underlying tariff scheme; instead it clarifies and prescribes which containers fall within item 57 by giving a precise definition and an exclusion. Mechanically, it narrows interpretive uncertainty rather than altering the substantive reach of item 57."},"complexity_factors":["Narrow, subject‑specific scope (only primary receptacles for Chapter 30 goods used for COVID‑19) reduces breadth of issues.","Relies on cross‑reference to item 57 of Schedule 4 and Chapter 30 of the Customs Tariff Act 1995—requires users to consult multiple instruments.","Single defined term ('primary receptacle') plus one explicit exclusion (ingestible capsules) keeps definitions limited but legally consequential.","Determination depends on both classification (Chapter 30) and intended use (treatment/prevention of COVID‑19), which may require evidentiary proof from importers.","Low administrative discretion in text (prescriptive definitions), but practical classification disputes may generate compliance burden and administrative queries."],"plain_english_summary":"This by-law tells customs which containers count as \"primary receptacles\" for item 57 of Schedule 4 to the Customs Tariff Act 1995: complete containers that directly hold COVID‑19 medicaments or vaccines classifiable under Chapter 30, excluding ingestible capsules. It changes how importers and manufacturers prove that a container qualifies for the tariff treatment tied to item 57, by fixing the technical definition and the COVID‑19 use test they must meet."}},"importantCases":[],"_links":{"self":"/api/acts/customs-by-law-no-2200084","history":"/api/acts/customs-by-law-no-2200084/history","analysis":"/api/acts/customs-by-law-no-2200084/analysis","conflicts":"/api/acts/customs-by-law-no-2200084/conflicts","importantCases":"/api/acts/customs-by-law-no-2200084/important-cases","documents":"/api/acts/customs-by-law-no-2200084/documents"}}